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August 24, 2010:742–6f such clinical trials may help to explain the relatively low awareness
f OSA as an important consideration in the patient with MI.
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Letters to the Editor
iscordance of
ndividual Risk Estimates
he excellent review by Berger et al. (1) perfectly illustrates a
roblem with individual risk prediction, which is that different
isk scores provide different risk estimates for the same patient. Hable 2 of their paper (1) shows estimated risks ranging from
% to 39% for a patient asking about her risk of a future
ardiovascular event. Much of this discordance represents the
ifferent outcomes and different time periods used in the various
ardiovascular risk scores. But even 10-year global cardiovascu-
ar risk ranges from 6% to 14%. This is a large discordance, and
ifferent preventive measures may be offered depending on the
hoice of a cardiovascular risk score.
When the U.S. Preventive Services Task Force published
uidelines on aspirin for prevention of cardiovascular disease,
orrespondents raised the same point, suggesting the guidelines be
eissued “with a specific risk-assessment tool that has been thor-
ughly studied to ensure the clinically appropriate application of
hese important guidelines” (2). The authors responded that
evelopment of a “gold-standard” cardiovascular disease risk cal-
ulator was a pressing priority (3). However, a recent review found
any examples of the discordance of individual risk estimates and
oncluded that such discordance was unavoidable (4). The reason
or this is that individuals do not have definite, pre-existing
robabilities of a cardiovascular outcome that can be precisely
stimated. In mathematical terms, the problem of risk stratification
oes not have a unique solution.
How do the authors manage such discordant individual risk
stimates in the clinic?
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e thank Dr. Stern for his interest in our paper (1), and agree
bout the difficult clinical challenge facing physicians in cardiovas-
ular prevention. How does one deal with seemingly discordant
isk scores in the clinical decision making process? Because the
oal of providers is to prevent or postpone the occurrence of
isease, understanding a patient’s risk of disease is essential.
evertheless, risk estimation is a probabilistic exercise rather than
definitive answer and therefore will always have some uncer-
ainty, even if we rely on a single “gold-standard” risk equation.
owever, there are a variety of risk scores that incorporate different
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August 24, 2010:742–6nd points over different periods of time. The patient in the
ignette has an estimated risk as low as 1% for a 10-year fatal
therosclerotic event, but as high as 39% for a lifetime cardiovas-
ular risk. Although this patient’s short-term risk may be low, the
atient’s lifetime risk is quite high and thus should be treated
ccordingly. Additionally, this woman could be categorized as
aving the metabolic syndrome with all 5 inclusion criteria:
besity, elevated triglycerides, low high-density lipoprotein, ele-
ated blood pressure, and abnormal fasting glucose (2).
The first goal for this patient would be lifestyle modification
ith an increase in physical activity and nutrition counseling. If the
ifestyle interventions are not sufficient to reduce her markers of
ncreased risk, it would be reasonable to consider starting her on an
ngiotensin-converting enzyme inhibitor and statin, with the goal
f preventing a first cardiovascular event and overt diabetes (3,4).
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ulse Pressure Amplification as
Predictor of Cardiovascular Risk
e read with interest the paper by Benetos et al. (1) regarding
ulse pressure amplification (PPA) as a predictor of cardiovascular
isk. We fully agree that measured PPA is an important cardiovas-
ular risk marker, because it reflects the level of central systolic/
ulse pressures for any given level of brachial pressures. However,
e would like to challenge the investigators’ conclusion that
omputed PPA based on standard risk factors, without the use of
ctual central pressure measurements, predicts cardiovascular risk
nd that “results were independent of any other confounding
actors.” The investigators generated a regression equation from a
ample of adults (n 834) to predict carotid pulse pressure (CPP). (hey identified age, sex, height, and glycemia as predictors of CPP
fter adjustment for brachial pulse pressure (BPP). The investiga-
ors present a model that predicts CPP with an impressive R2
85.8% predicted variability). However, BPP alone predicted
3.5% of the CPP variability, all the other terms providing as little
s a 2.3% increase in R2 (corresponding to 10% of the CPP
ariability not explained by BPP). The investigators provide no
vidence of the external validity of their equation, proceeding to
pply it to a large population (n  125,151). They concluded that
he estimated carotid/brachial pulse pressure ratio (C/B ratio) was
redictive of cardiovascular and all-cause death and that “results
ere independent of any other confounding factors.” To the degree
hat the estimated C/B ratio is a simple function of BPP and
lassic cardiovascular risk factors, it cannot possibly have true
ndependent value beyond those factors. The calculated C/B ratio
s necessarily correlated with BPP, hence its prognostic value after
djustment for age and sex. The marginal increase in adjusted
tandardized hazard ratios over BPP is likely due to the prognostic
ffect of body height, which is used to estimate the C/B ratio (and
herefore bears an independent association with it). Body height
tself is associated with increased cardiovascular risk (2) and was
ot included in proportional hazards models. Furthermore, the
nvestigators provided no evidence of statistical superiority of
odels including the estimated C/B ratio over those including
PP or any data reflecting actual model performance (such as
kaike’s information criteria or C-statistics). Had the investigators
ompared a model including age, sex, BPP, body height, and
lycemia with a model containing the computed C/B ratio,
rediction of cardiovascular death would have been superior with
he former.
There is a need to continue to gain understanding regarding the
echanisms and the predictive value of central hemodynamics, but
he benefit of PPA as a marker of cardiovascular risk lies in the
arge variability that cannot be predicted by standard risk factors,
herefore requiring actual assessments via pulse wave analysis,
ather than on the relatively small variability that can be predicted
ith the reported regression equation.
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n the past, blood pressure measurements were devoted to the
iagnosis and treatment of threatening accidents. Currently, the
oal of measurements has changed and became prevention, but
he devices remained almost identical. For example, pulse pressure
PP) amplification (1,2), described 50 years ago, is yet poorly used
